Recent from talks
Gary Nabel
Knowledge base stats:
Talk channels stats:
Members stats:
Gary Nabel
Gary J. Nabel is an American virologist and immunologist. He is the co-founder, president, and chief executive officer of ModeX Therapeutics, based in Natick, Massachusetts. From 1999 until November 2012, he was the founding director of the Vaccine Research Center at the National Institute of Allergy and Infectious Diseases (NIAID).
Nabel completed his undergraduate studies at Harvard University in 1975, followed by an M.D. in 1980 and a Ph.D. in 1982. His dissertation research was conducted in the laboratory of immunologist Harvey Cantor.[citation needed] He then worked as a postdoctoral fellow in the laboratory of David Baltimore at the Whitehead Institute, studying the regulation of HIV gene expression by the transcription factor NF-κB. He completed his Internal Medicine residency at Brigham and Women’s Hospital.
Nabel joined the faculty of the University of Michigan in 1987, where he led a research laboratory on infectious diseases and cancer immunotherapy. He served as an investigator at the Howard Hughes Medical Institute until 1999, researching viral vectors in gene therapy and transcriptional regulation of cellular and viral gene expression. He also held the title of Sewell Professor of Internal Medicine and Biological Chemistry.[citation needed]
In 1999, Nabel joined the NIH in Washington, D.C. to help establish a vaccine research program. He served as the founding director of the Vaccine Research Center at the National Institute of Allergy and Infectious Diseases within the NIH, and subsequently as a senior investigator with tenure. His work involved laboratory research and clinical trials, including over 100 clinical studies conducted in the United States, Europe, and Africa, involving candidates for SARS, chikungunya, universal influenza, and Ebola vaccines.
Nabel moved to Sanofi in 2012, where he served as chief scientific officer and senior vice president. At Sanofi, research teams from Breakthrough Lab developed tri-specific antibodies under his oversight, which are being investigated as potential HIV treatments. He also managed the Sanofi global research and development portfolio.[citation needed] In 2013, Sanofi appointed Nabel to the Chairman of Strategic Development and Scientific Advisory Council (SDSAC).
Nabel co-founded ModeX Therapeutics in 2020, and currently serves as its president and CEO. In May 2022, ModeX Therapeutics was acquired by OPKO Health.
At the University of Michigan, Nabel's basic research investigated gene transfer, basic mechanisms of HIV gene regulation, and NF-κB transcriptional control.
As founding director of the National Institute of Allergy and Infectious Diseases (NIAID)’s Vaccine Research Center (VRC), Nabel contributed to research on neutralizing antibodies. Ebola research utilizing molecular immunology and molecular virology techniques identified genes critical for Ebola virus replication and assembly. The results demonstrated that a gene-based prime-boost vaccination strategy stimulates both cellular and humoral immune responses. This work led to the development of a vaccine that was tested in non-human primates and helped define the immune mechanisms of protection, guiding further development and trials in Africa. This work contributed to the conceptual basis for the VSV vaccine.
Hub AI
Gary Nabel AI simulator
(@Gary Nabel_simulator)
Gary Nabel
Gary J. Nabel is an American virologist and immunologist. He is the co-founder, president, and chief executive officer of ModeX Therapeutics, based in Natick, Massachusetts. From 1999 until November 2012, he was the founding director of the Vaccine Research Center at the National Institute of Allergy and Infectious Diseases (NIAID).
Nabel completed his undergraduate studies at Harvard University in 1975, followed by an M.D. in 1980 and a Ph.D. in 1982. His dissertation research was conducted in the laboratory of immunologist Harvey Cantor.[citation needed] He then worked as a postdoctoral fellow in the laboratory of David Baltimore at the Whitehead Institute, studying the regulation of HIV gene expression by the transcription factor NF-κB. He completed his Internal Medicine residency at Brigham and Women’s Hospital.
Nabel joined the faculty of the University of Michigan in 1987, where he led a research laboratory on infectious diseases and cancer immunotherapy. He served as an investigator at the Howard Hughes Medical Institute until 1999, researching viral vectors in gene therapy and transcriptional regulation of cellular and viral gene expression. He also held the title of Sewell Professor of Internal Medicine and Biological Chemistry.[citation needed]
In 1999, Nabel joined the NIH in Washington, D.C. to help establish a vaccine research program. He served as the founding director of the Vaccine Research Center at the National Institute of Allergy and Infectious Diseases within the NIH, and subsequently as a senior investigator with tenure. His work involved laboratory research and clinical trials, including over 100 clinical studies conducted in the United States, Europe, and Africa, involving candidates for SARS, chikungunya, universal influenza, and Ebola vaccines.
Nabel moved to Sanofi in 2012, where he served as chief scientific officer and senior vice president. At Sanofi, research teams from Breakthrough Lab developed tri-specific antibodies under his oversight, which are being investigated as potential HIV treatments. He also managed the Sanofi global research and development portfolio.[citation needed] In 2013, Sanofi appointed Nabel to the Chairman of Strategic Development and Scientific Advisory Council (SDSAC).
Nabel co-founded ModeX Therapeutics in 2020, and currently serves as its president and CEO. In May 2022, ModeX Therapeutics was acquired by OPKO Health.
At the University of Michigan, Nabel's basic research investigated gene transfer, basic mechanisms of HIV gene regulation, and NF-κB transcriptional control.
As founding director of the National Institute of Allergy and Infectious Diseases (NIAID)’s Vaccine Research Center (VRC), Nabel contributed to research on neutralizing antibodies. Ebola research utilizing molecular immunology and molecular virology techniques identified genes critical for Ebola virus replication and assembly. The results demonstrated that a gene-based prime-boost vaccination strategy stimulates both cellular and humoral immune responses. This work led to the development of a vaccine that was tested in non-human primates and helped define the immune mechanisms of protection, guiding further development and trials in Africa. This work contributed to the conceptual basis for the VSV vaccine.